home / stock / bctxw / bctxw news

BCTXW News and Press, BriaCell Therapeutics Corp. Warrant From 10/21/25

Stock Information
Company Name: BriaCell Therapeutics Corp. Warrant
Stock Symbol: BCTXW
Market: NASDAQ
Website: briacell.com
Menu
BCTXW BCTXW Quote BCTXW Short BCTXW News BCTXW Articles BCTXW Message Board
Get BCTXW Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTXW - BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University have now joined BriaCell’s ...
BCTXW - BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+(TM) for Breast Cancer

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2...

BCTXW - BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) No new safety or tolerability issues identified in pooled analysis of ongoing pivotal Phase 3 ...

BCTXW - BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC) Positive delayed-type hypersensitivity (DTH) – a potential biomarker predictive of improved clinical outcomes – signif...
BCTXW - BriaCell to Present Bria-OTS+(TM) Preclinical Data at SITC 2025 Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform ca...

BCTXW - BriaCell's Bria-OTS+(TM) Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platform Bria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for pat...

BCTXW - BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+(TM) in Prostate Cancer

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+ TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to ...
BCTXW - BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+(TM) for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology company that develops novel immunotherapie...

BCTXW - BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology company that develops novel immunotherapies to ...

BCTXW - BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cance...
Previous 10 Next 10